Anteris Technologies Announces Results for the Third Quarter of 2026
Key Highlights
- ➤PARADIGM Trial expanded to Germany and Australia after quarter-end regulatory approvals
- ➤PARADIGM Trial enrollment progressed across active sites in the U.S., Canada, Denmark, Netherlands and France
- ➤$22.9 million net operating cash outflows recorded in Q3 2026
- ➤$21.3 million R&D expenses funded manufacturing scale-up and PARADIGM activities
- ➤Northcross facility occupancy adds production capacity for DurAVR THVs and ComASUR systems
Expert Statements
Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris
“Q3 saw continued progress on multiple fronts. The PARADIGM Trial recruitment is advancing along with capacity expansion in line with our clinical and commercial plan. The Company also brought in some key hires to strengthen our operating model and future capabilities.”
MINNEAPOLIS and BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended September 30, 2026, and provided a corporate update.
Q3 2026 Highlights * Continued execution of the PARADIGM Trial, with enrollment progressing across active sites in the U.S., Canada, Denmark, the Netherlands and France. Subsequent to quarter-end, the trial received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) and advanced in Australia following HREC approval and TGA authorization under the Clinical Trial Notification pathway. * Assumed occupancy of the Northcross facility in Minnesota, providing additional capacity to scale production of the DurAVR(®) THVs and ComASUR(®) Delivery System, in preparation for commercialization. * Appointed Brent Moen as Chief Financial Officer, effective September 11, to support the Company’s financial and governance priorities as it advances the DurAVR THV toward commercialization. “Q3 saw continued progress on multiple fronts. The PARADIGM Trial recruitment is advancing along with capacity expansion in line with our clinical and commercial plan. The Company also brought in some key hires to strengthen our operating model and future capabilities,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris.
Get started
Create a free account to read the full story.